Literature DB >> 29299416

Can we omit radiotherapy in case of brain metastases for patients with mutant EGFR lung adenocarcinoma?

Paul Jules Van Houtte1, Daniel Devriendt1.   

Abstract

Entities:  

Year:  2017        PMID： 29299416      PMCID： PMC5750151          DOI： 10.21037/tlcr.2017.10.08

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  13 in total

1.  Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors.

Authors:  Vinai Gondi; Bruce P Hermann; Minesh P Mehta; Wolfgang A Tomé
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-29       Impact factor: 7.038

2.  Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.

Authors:  Mark K Doherty; Grzegorz J Korpanty; Pascale Tomasini; Moein Alizadeh; Kevin Jao; Catherine Labbé; Celine M Mascaux; Petra Martin; Suzanne Kamel-Reid; Ming-Sound Tsao; Melania Pintilie; Geoffrey Liu; Penelope A Bradbury; Ronald Feld; Natasha B Leighl; Caroline Chung; Frances A Shepherd
Journal:  Radiother Oncol       Date:  2017-03-28       Impact factor: 6.280

3.  Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

Authors:  William J Magnuson; Nataniel H Lester-Coll; Abraham J Wu; T Jonathan Yang; Natalie A Lockney; Naamit K Gerber; Kathryn Beal; Arya Amini; Tejas Patil; Brian D Kavanagh; D Ross Camidge; Steven E Braunstein; Lauren C Boreta; Suresh K Balasubramanian; Manmeet S Ahluwalia; Niteshkumar G Rana; Albert Attia; Scott N Gettinger; Joseph N Contessa; James B Yu; Veronica L Chiang
Journal:  J Clin Oncol       Date:  2017-01-23       Impact factor: 44.544

4.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.

Authors:  L Gaspar; C Scott; M Rotman; S Asbell; T Phillips; T Wasserman; W G McKenna; R Byhardt
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-01       Impact factor: 7.038

5.  Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems.

Authors:  José Lorenzoni; Daniel Devriendt; Nicolas Massager; Phillippe David; Salvador Ruíz; Bruno Vanderlinden; Paul Van Houtte; Jacques Brotchi; Marc Levivier
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-09-01       Impact factor: 7.038

6.  Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.

Authors:  SongRan Liu; Bo Qiu; LiKun Chen; Fang Wang; Ying Liang; PeiQiang Cai; Li Zhang; ZhaoLin Chen; ShiLiang Liu; MengZhong Liu; Hui Liu
Journal:  Radiat Oncol       Date:  2015-05-27       Impact factor: 3.481

7.  Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).

Authors:  Qianqian Zhu; Yanan Sun; Yingying Cui; Ke Ye; Chengliang Yang; Daoke Yang; Jie Ma; Xiao Liu; Jinming Yu; Hong Ge
Journal:  Oncotarget       Date:  2017-02-21

8.  Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.

Authors:  Seonggyu Byeon; Jun Soo Ham; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  Med Oncol       Date:  2016-07-22       Impact factor: 3.064

9.  Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis.

Authors:  Tao Jiang; Weijie Min; Yanan Li; Zhijian Yue; Chunyan Wu; Caicun Zhou
Journal:  Cancer Med       Date:  2016-03-14       Impact factor: 4.452

10.  First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.

Authors:  Yongshun Chen; Jing Yang; Xue Li; Daxuan Hao; Xiaoyuan Wu; Yuanyuan Yang; Chunyu He; Wen Wang; Jianhua Wang
Journal:  Cancer Sci       Date:  2016-11-25       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.